Velaglucerase alfa

From WikiMD's Wellness Encyclopedia

(Redirected from VPRIV)

What is Velaglucerase alfa?[edit | edit source]

  • Velaglucerase alfa (VPRIV) is a hydrolytic lysosomal glucocerebroside-specific enzyme used as a long-term enzyme replacement therapy for those suffering of Gaucher disease Type 1.


RECALLED – VPRIV® (velaglucerase alfa for injection) (13265840234).jpg


What are the uses of this medicine?[edit | edit source]

How does this medicine work?[edit | edit source]

  • Velaglucerase alfa catalyzes the hydrolysis of glucocerebroside, reducing the amount of accumulated glucocerebroside.

In clinical trials VPRIV reduced spleen and liver size, and improved anemia and thrombocytopenia.

  • Velaglucerase is produced in a human cell line using gene activation technology, resulting in production of a recombinant protein with the identical amino acid sequence as the native, human enzyme.
  • The glucocerebrosidase producing cells are treated with enzymes that modify glycosylation and result in high-mannose type glycans which increase uptake of the velaglucerase by macrophages.

Who Should Not Use this medicine ?[edit | edit source]

  • This medicine have no usage limitations.

What drug interactions can this medicine cause?[edit | edit source]

  • No formal drug interaction studies have been conducted with VPRIV.

Is this medicine FDA approved?[edit | edit source]

  • Velaglucerase was approved for use as enzyme replacement therapy of type 1 [[[Gaucher disease]] in the United States in 2010.
  • It is available as a lyophilized powder in single use vials of 400 Units under the brand name Vpriv. The typical initial dose is 60 Units/kg intravenously every 2 weeks.

How should this medicine be used?[edit | edit source]

Recommended dosage: Recommended Starting Dose in Adults and Pediatric Patients 4 Years of Age or Older:

  • Patients Naïve to Enzyme Replacement Therapy: 60 Units/kg
  • Patients being treated with stable imiglucerase dosages for Gaucher disease: Can switch to VPRIV at previous imiglucerase dose two weeks after last imiglucerase dose
  • Consider pre-treatment with antihistamines and/or corticosteroids in patients who exhibited symptoms of hypersensitivity associated with prior velaglucerase alfa product infusions.

Administration:

  • Determine number of vials to be reconstituted based on patient's actual weight and prescribed dose.
  • Supplied VPRIV lyophilized powder must be reconstituted with Sterile Water for Injection.
  • Reconstituted VPRIV solution must be diluted in 100 mL of 0.9% Sodium Chloride Injection prior to intravenous infusion.
  • Administer the diluted VPRIV solution through an in-line low protein-binding 0.2 or 0.22 µm filter over 60 minutes.
  • Do not infuse VPRIV with other products in the same infusion tubing because the compatibility of a VPRIV solution with other products has not been evaluated.

What are the dosage forms and brand names of this medicine?[edit | edit source]

This medicine is available in fallowing doasage form:

  • As injection: 400 units lyophilized powder single-dose vials

This medicine is available in fallowing brand namesː

  • VPRIV

What side effects can this medication cause?[edit | edit source]

The most common side effects of this medicine include:


What special precautions should I follow?[edit | edit source]

  • Hypersensitivity reactions, including anaphylaxis, occurred in clinical studies and postmarketing experience. In cases where patients have exhibited symptoms of hypersensitivity to velaglucerase alfa or excipients in the drug product or to other enzyme replacement therapy, pre-treatment with antihistamines and/or corticosteroids may prevent subsequent reactions.
  • Ensure that personnel administering product are adequately trained in cardiopulmonary resuscitative measures, and have ready access to emergency medical services.
  • Consider slowing infusion rate, treatment with antihistamines, antipyretics and/or corticosteroids, and/or stopping treatment if a hypersensitivity reaction occurs during an infusion. Consider pre-treatment with antihistamines and/or corticosteroids in patients with prior reactions.

What to do in case of emergency/overdose?[edit | edit source]

  • In case of overdose, call the poison control helpline of your country. In the United States, call 1-800-222-1222.

Can this medicine be used in pregnancy?[edit | edit source]

  • While available data cannot definitively establish or exclude the absence of a velaglucerase alfa associated risk during pregnancy, these data have not identified an association with use of velaglucerase alfa during pregnancy and major birth defects, miscarriage, or adverse maternal or fetal outcomes.

Can this medicine be used in children?[edit | edit source]

  • The safety and effectiveness of VPRIV have been established for enzyme replacement therapy (ERT) in patients between 4 and 17 years of age with type 1 Gaucher disease.
  • The efficacy and safety of VPRIV has not been established in pediatric patients younger than 4 years of age.

What are the active and inactive ingredients in this medicine?[edit | edit source]

Active ingredient:

  • VELAGLUCERASE ALFA

Inactive ingredients:

  • CITRIC ACID MONOHYDRATE
  • POLYSORBATE 20
  • TRISODIUM CITRATE DIHYDRATE
  • SUCROSE

Who manufactures and distributes this medicine?[edit | edit source]

  • Manufactured by:

Takeda Pharmaceuticals U.S.A., Inc. Lexington, MA

What should I know about storage and disposal of this medication?[edit | edit source]

  • Store VPRIV refrigerated at 2ºC to 8ºC (36ºF to 46ºF) in the original carton to protect from light.
  • Do not freeze.
  • Do not use VPRIV after the expiration date on the vial.

genetic disorder agents[edit source]

cystic fibrosis agents

enzyme replacement therapy

glucosylceramide synthase inhibitors (substrate restriction therapy)

lysosomal acid lipase deficiency agents

miscellaneous

homocystinuria agents

Huntington disease agents

Monoclonal Antibodies

Tyrosinemia Agents

Urea Cycle Disorder Agents

Hematologic Agents

Velaglucerase alfa Resources
Wikipedia

WikiMD
Navigation: Wellness - Encyclopedia - Health topics - Disease Index‏‎ - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes

Search WikiMD

Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD

WikiMD's Wellness Encyclopedia

Let Food Be Thy Medicine
Medicine Thy Food - Hippocrates

Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.

Contributors: Prab R. Tumpati, MD